Cash-pay menopause narrows market
Midi Health
Cash pay menopause care is structurally easier to run, but it wins by narrowing the customer to women willing to spend out of pocket for speed, convenience, and clear pricing. That tradeoff is why Alloy and Evernow can stay operationally simple, while Midi built around insurance reimbursement and employer benefits to reach a much larger pool of women who would not subscribe to a $40 to $50 monthly service on top of normal healthcare costs.
-
In practice, cash pay removes the slowest parts of healthcare billing. No claim submission, no prior authorization workflow for each visit, no waiting months for reimbursement, and less staff spent on coding and collections. A menopause clinic can market a flat fee, schedule a video visit, prescribe, and charge the card immediately.
-
The limit is simple math. A woman with insurance can often justify a covered telehealth visit, but a recurring subscription plus medication spend is a discretionary purchase. That pushes cash pay toward higher income, urgency driven users, while insurance based models can sell into employers and health plans as a broad benefit across a workforce.
-
This is why the market is splitting into two lanes. Alloy and Evernow look more like premium consumer health brands, with transparent pricing and lighter operations. Midi looks more like a specialty virtual clinic, using insurance verification, longer visits, follow ups, and employer distribution to trade more admin complexity for wider access and bigger scale.
Going forward, the winners will be the companies that pair menopause expertise with the cheapest distribution channel. Cash pay players will keep moving into pharmacy and product attachment to raise revenue per member, while insurance based players will keep expanding through employers, payers, and broader midlife care so menopause becomes a covered entry point into a larger women’s health platform.